Royal Fund Management LLC Acquires 2,990 Shares of AbbVie Inc. $ABBV

Royal Fund Management LLC grew its holdings in AbbVie Inc. (NYSE:ABBV) by 6.3% in the 2nd quarter, according to the company in its most recent filing with the SEC. The firm owned 50,828 shares of the company’s stock after buying an additional 2,990 shares during the quarter. AbbVie makes up about 1.1% of Royal Fund Management LLC’s investment portfolio, making the stock its 20th largest holding. Royal Fund Management LLC’s holdings in AbbVie were worth $12,791,000 as of its most recent SEC filing.

Several other hedge funds have also recently made changes to their positions in the business. Venturi Wealth Management LLC raised its holdings in shares of AbbVie by 1.1% during the second quarter. Venturi Wealth Management LLC now owns 100,019 shares of the company’s stock valued at $25,169,000 after acquiring an additional 1,100 shares in the last quarter. KRS Capital Management LLC lifted its stake in AbbVie by 2.6% in the second quarter. KRS Capital Management LLC now owns 8,572 shares of the company’s stock worth $2,157,000 after acquiring an additional 219 shares during the period. Selective Wealth Management Inc. bought a new stake in AbbVie in the second quarter valued at $218,000. Aspiriant LLC increased its position in AbbVie by 8.4% during the 2nd quarter. Aspiriant LLC now owns 10,553 shares of the company’s stock valued at $2,656,000 after purchasing an additional 818 shares during the period. Finally, Brown Wealth Management LLC increased its position in AbbVie by 4.7% during the 2nd quarter. Brown Wealth Management LLC now owns 1,722 shares of the company’s stock valued at $433,000 after purchasing an additional 77 shares during the period. 70.23% of the stock is owned by hedge funds and other institutional investors.

Key Headlines Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Strong post-Humira growth: AbbVie reported first-quarter 2026 revenue of $15.002 billion, up 12.4% year over year on a reported basis and 10.3% operationally. Adjusted diluted EPS of $2.65 exceeded internal expectations despite a $0.41-per-share headwind from acquired in-process research and development costs, supporting confidence in the company’s ability to replace Humira-related sales. Could AbbVie Inc. (ABBV)’s Post-Humira Transformation Drive the Next Phase of Growth?
• Positive Sentiment: Analyst support strengthened: Wolfe Research upgraded AbbVie, citing the company’s pipeline strength and valuation. BNP Paribas Exane also indicated that the stock could rise, adding to the bullish research tone. Wolfe Research upgrades Biogen, AbbVie on pipeline strength and valuation AbbVie Stock Price Expected to Rise, BNP Paribas Exane Analyst Says
• Positive Sentiment: Commercial and pipeline catalysts: AbbVie’s Botox filing and Canada’s reimbursement recommendation for UBRELVY in adult migraine treatment could expand revenue opportunities in aesthetics and neuroscience. AbbVie Wins Canada Reimbursement Backing for Adult Migraine Treatment
• Neutral Sentiment: Updates on venetoclax in high-risk myelodysplastic syndromes and a completed Phase 3 Botox jawline study provide potential longer-term catalysts, but their financial impact depends on additional data, regulatory decisions, and commercialization. AbbVie’s Venetoclax Combo in High-Risk MDS
• Negative Sentiment: Erste Group Bank lowered its AbbVie earnings estimates, highlighting a counterpoint to the positive upgrades and potentially limiting near-term upside. Erste Group Bank Lowers Earnings Estimates for AbbVie

AbbVie Trading Up 1.0%

Shares of NYSE:ABBV opened at $251.20 on Friday. The stock has a fifty day simple moving average of $244.51 and a two-hundred day simple moving average of $225.96. The stock has a market capitalization of $443.82 billion, a price-to-earnings ratio of 70.96, a PEG ratio of 0.82 and a beta of 0.30. AbbVie Inc. has a 12-month low of $190.75 and a 12-month high of $267.47.

AbbVie (NYSE:ABBV) last released its earnings results on Friday, July 31st. The company reported $3.65 EPS for the quarter, topping analysts’ consensus estimates of $3.61 by $0.04. The firm had revenue of $16.99 billion for the quarter, compared to analysts’ expectations of $16.80 billion. AbbVie had a negative return on equity of 422.07% and a net margin of 9.80%.The company’s quarterly revenue was up 10.2% on a year-over-year basis. During the same period in the prior year, the firm posted $2.97 earnings per share. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. As a group, equities research analysts predict that AbbVie Inc. will post 14.07 EPS for the current year.

AbbVie Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, August 14th. Shareholders of record on Wednesday, July 15th will be issued a $1.73 dividend. The ex-dividend date of this dividend is Wednesday, July 15th. This represents a $6.92 annualized dividend and a yield of 2.8%. AbbVie’s payout ratio is 195.48%.

Analyst Ratings Changes

Several research firms have recently commented on ABBV. Royal Bank Of Canada raised their target price on shares of AbbVie from $260.00 to $280.00 and gave the stock an “outperform” rating in a research report on Friday, July 10th. Canaccord Genuity Group boosted their price target on shares of AbbVie from $282.00 to $290.00 and gave the company a “buy” rating in a research report on Monday, August 3rd. DZ Bank raised shares of AbbVie from a “hold” rating to a “strong-buy” rating in a research note on Thursday, April 30th. Sanford C. Bernstein restated a “market perform” rating on shares of AbbVie in a report on Tuesday, June 23rd. Finally, Cantor Fitzgerald lifted their price objective on AbbVie from $265.00 to $285.00 and gave the company an “overweight” rating in a research report on Monday, August 3rd. Two investment analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and five have given a Hold rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $275.50.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.